• Edgewater Capital Partners sold Prolytix, a regulated bioanalytical and CMC services provider, to VION Biosciences on Sept. 9, 2026.
• Deal expands VION’s integrated life sciences platform spanning research, diagnostics, and drug development workflows.
• Prolytix adds large-molecule bioanalytical and CMC capabilities, extending support for biopharma and diagnostic customers across development stages.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewater Capital Partners LP published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.